News | August 17, 2023
Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients
Jeet will be a trusted partner in cardiovascular care
Jeet will be a trusted partner in cardiovascular care
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Final decision from the European Commission is anticipated within the coming months
Subscribe To Our Newsletter & Stay Updated
